Visualitzant per matèria "Biosimilar"
Ara mostrant els elements 1-1 de 1
-
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: preclinical and real-life clinical data
(The Breast, 2022, 62: 1-9, 2022-01)After the expiration of trastuzumab data exclusivity, biosimilar drugs were approved by regulatory agencies; among them, CT-P6 which was approved for the treatment of HER2-positive early- and advanced-breast ...